Terns Pharmaceuticals (TERN) Stock Price, News & Analysis

Company Overview

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for liver diseases. Headquartered in San Diego, California, Terns focuses on addressing unmet needs in metabolic and cholestatic liver disorders as well as viral hepatitis. The company’s research platform leverages proprietary bile acid chemistry and nuclear hormone receptor modulation to advance compounds with the potential to alter disease pathways in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and chronic hepatitis B virus (HBV) infection.

Terns’ lead programs include TERN-201, a proprietary norursodeoxycholic acid (norUDCA) derivative engineered to improve cholestatic liver function in PSC and PBC, and TERN-301, an oral capsid assembly inhibitor targeting HBV replication. Additional pipeline candidates such as TERN-501, a selective farnesoid X receptor (FXR) agonist, and other bile acid–based analogs are in preclinical or early clinical development for NASH and related metabolic liver conditions. By combining structure-based drug design with in vivo models of liver disease, the company aims to deliver differentiated assets capable of improving key biochemical and histologic measures of liver health.

Founded in 2018, Terns Pharmaceuticals completed its initial public offering on the Nasdaq exchange in 2021 under the ticker symbol TERN. The company’s executive team is led by President and Chief Executive Officer Helen Gao, Ph.D., whose background spans small-molecule drug discovery and clinical development in hepatology. Terns collaborates with leading academic centers in North America and Europe to support its clinical trials and regulatory efforts. With a global focus on liver disease patients, the company plans to advance its portfolio through proof-of-concept studies and to forge partnerships aimed at broadening patient access worldwide.

Key Stats

• Today's Range: $4.60 to $4.92
• 50-Day Range: $2.78 to $4.53
• 52-Week Range: $1.87 to $11.40
• Volume: 806,589 shs
• Average Volume: 1.47 million shs
• Market Capitalization: $420.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.63
• Consensus Rating: Moderate Buy

Terns Pharmaceuticals Stock Analysis - MarketRank™

Terns Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 241st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Terns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Terns Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Terns Pharmaceuticals is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Terns Pharmaceuticals is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Terns Pharmaceuticals has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.94% of the float of Terns Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Terns Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Terns Pharmaceuticals has recently increased by 9.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Terns Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Terns Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -0.95

Percentage of Shares Shorted

8.94% of the float of Terns Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Terns Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Terns Pharmaceuticals has recently increased by 9.19%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.50

News Sentiment

Terns Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Terns Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

12 people have searched for TERN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Terns Pharmaceuticals insiders have bought 5,022.87% more of their company's stock than they have sold. Specifically, they have bought $186,575.00 in company stock and sold $3,642.00 in company stock.

Percentage Held by Insiders

Only 1.50% of the stock of Terns Pharmaceuticals is held by insiders.

Percentage Held by Institutions

98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TERN Stock Analysis - Frequently Asked Questions

How have TERN shares performed this year?

Terns Pharmaceuticals' stock was trading at $5.54 at the start of the year. Since then, TERN shares have decreased by 14.6% and is now trading at $4.7320.

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) announced its earnings results on Thursday, May, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03.

When did Terns Pharmaceuticals IPO?

Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Terns Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TERN
• CIK: 1831363
• Web: www.ternspharma.com
• Phone: 650-525-5535
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Terns Pharmaceuticals: $15.63
• High Price Target: $20.00
• Low Price Target: $7.50
• Potential Upside/Downside: +244.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$88.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -28.81%
• Return on Assets: -27.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 30.89
• Quick Ratio: 30.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.07 per share
• Price / Book: 1.11

Miscellaneous

• Outstanding Shares: 87,340,000
• Free Float: 86,027,000
• Market Cap: $395.65 million
• Optionable: Not Optionable
• Beta: -0.11